

Supplemental Figure S1. Levels of *mcr* are decreased after NMDA-treatment, the MCR-agonist aldosterone has little effect upon the proliferation of MGPCs, and aldosterone does not influence FGF2/MAPK-signaling. A; qRT-PCR was used to measure levels of mRNA for *mcr* at 4 hrs, 1 day, 2 days and 3 days after NMDA-treatment. The histogram illustrates the mean (\pm SD; n=4) percentage change of mRNA. Significance of difference between control and treated groups was determined by using a two-tailed Mann-Whitney U test (**p<0.01, ns-not significant). **B** and **C**; histograms illustrate the mean (\pm SD; n=8) number of proliferating MGPCs or NIRG cells per field of view in retinas treated with NMDA + vehicle (control) or NMDA + aldosterone (treated). Significance of difference (ns - not significant) for treated vs control data sets was determined by using a two-tailed, paired t-test. **D-K**; Retinas were obtained from eyes that were injected 2 consecutive days with FGF2 \pm aldosterone, and harvested 24 hrs after the last injection. Retinal sections were labeled with antibodies to pERK1/2 (**D** and **E**; green), cFos (**F** and **G**; green), Egr1 (**H** and **I**; green), pS6 (**J** and **K**; green), Sox2 (**D-G**, **J**, **K**; red) or Sox9 (**H** and **I**; red). Hollow arrowheads indicate the nuclei of Müller glia. The 50 µm bar in **K** applies to **D-K**.

Gene	Forward primer 5'-3'	rd primer 5'-3' Reverse primer 5'-3'	
gcr	AAC CTG CTC TGG CTG ACT TC	GCC TGA AGT CCG TTT CTC CA	186
hsd1	GGT GCA GAT GGT CTC ACA CA	CAG AAA CTC GGG AGC AAG GT	163
hsd2	AAA GTC AGC CTC ATC CTG CC	TGA ACT GCC GGT TGA TCT CC	154
mcr	TCA AAA CCA GAC ACA GCC GA	GGT CCT CGA GAG GCA AGT TT	124
il6	TTA GTT CGG GCA CAA TCC TC	GGT TCC TGA AAC GGA ACA AC	72
il6Ra	AAA GAT GTG CTC TGC GAG TG	AAC CTG CGC TTC ATC CAT AG	80
il1β	GCA TCA AGG GCT ACA AGC TC	CAG GCG GTA GAA GAT GAA GC	131
tnfa	AGC AGC GTT TGG GAG TGG GC	GCA GAT GGG GCA GGA AAG CCA	133
adam17	AGC GAG TGC CCT CCT CCT GG	TTG CAG GCA CAC GAG CGG AG	125
cNotch1	GGC TGG TTA TCA TGG AGT TA	CAT CCA CAT TGA TCT CAC AG	154
cDelta1	CAC TGA CAA CCC TGA TGG TG	TGG CAC TGG CAT ATG TAG GA	152
cDll4	GGT CTG CAG CGA GAA CTA CT	TGC AGT ATC CAT TCT GTT CG	181
cJag1	TGA TAA GTG CAT TCC ACA CC	CAG GTA CCA CCA TTC AAA CA	149
cHes1	CGC TGA AGA AGG ATA GTT CG	GTC ACT TCG TTC ATG CAC TC	175
cHes5	GGA GAA GGA GTT CCA GAG AC	AAT TGC AGA GCT TCT TTG AG	143
ascl1a	AGG GAA CCA CGT TTA TGC AG	TTA TAC AGG GCC TGG TGA GC	187
сЗ	TCC CCC ATG AGG AAT GGG AT	ATA GTC CAT GTC CCC AGG CT	74
c3aR	CACT CGC ATA TGC CAA CAG C	GCC TTT GCT CTG AAG TCC CT	73
gapdh	CAT CCA AGG AGT GAG CCA AG	TGG AGG AAG AAA TTG GAG GA	161

Supplementary Table S1. PCR Primer sequences and predicted product sizes

Antigen	Working	Host	Clone or catalog	Source
Duimour			number	
Primary				
GCR	1:400	rabbit	PA1-511A	Thermo Scientific
GCR	1:500	rabbit	H-300 sc-8992	Santa Cruz Immunochemicals
Sox2	1:1000	goat	Y-17	Santa Cruz Immunochemicals
Sox9	1:2500	rabbit	AB5535	Millipore
				Billerica, MA
Nkx2.2	1:80	mouse	74.5A5	Developmental Studies Hybridoma
				Bank (DSHB)
				Iowa City, IA
Top _{AP}	1:100	mouse	2M6	Dr. P. Linser
				University of Florida
BrdU	1:200	rat	OBT00030S	AbD Serotec
				Raleigh, NC
Egr1	1:1000	goat	AF2818	R&D Systems
pERK1/2	1:200	rabbit	137F5	Cell Signaling Technologies
cFos	1:400	rabbit	K-25	Santa Cruz Immunochemicals
pS6	1:400	rabbit	2215	Cell Signaling Technologies
neurofilament	1:50	mouse	RT97	DSHB
CD45	1:200	mouse	HIS-C7	Cedi Diagnostic
p38 MAPK	1:400	rabbit	12F8	Cell Signaling Technologies
pCREB	1:500	rabbit	87G3	Cell Signaling Technologies
Secondary				
antibodies				
Goat IgG	1:1000	donkey	Alexa488/568	Invitrogen
Rabbit IgG	1:1000	goat	Alexa488/568/647	Invitrogen
Mouse IgG	1:1000	goat	Alexa488/568/647	Invitrogen
Rat IgG	1:1000	goat	Alexa488	Invitrogen

Supplementary Table S2. Antibodies, sources and working dilutions.